Navigation Links
Discovery of variations in resistance to sulfadoxine across Africa
Date:4/14/2009

Researchers have discovered that malaria parasites in east and west Africa carry different resistance mutations, which suggests that the effectiveness of sulfadoxine as an antimalarial drug may vary across Africa.

The findings have implications for the manner in which malaria control campaigns are carried out, and suggest that coordinating efforts between parts of Africa that share similar patterns of resistance is likely to be more effective than working in isolation in each country.

Plasmodium falciparum (P. falciparum) a mosquito-borne parasite that causes malaria, kills nearly one million people a year, mostly in sub-Saharan Africa. Until recently, treatment in Africa relied on chloroquine and sulfadoxine-pyrimethamine. Unfortunately, parasites have developed resistance to both these drugs by acquiring 'resistance mutations', genetic changes that prevent the drugs from killing them.

Scientists have discovered that the mutations that caused resistance to chloroquine and pyrimethamine originated in Asia and spread into Africa in the late 1970s and early 1980s respectively. These mutations are now common across Africa and it is no longer possible to determine how they spread across the continent. However, the mutations that cause resistance to sulfadoxine only began to emerge in the mid-1990s, and have not yet spread evenly across Africa.

A study published today in PloS Medicine, and led by Dr. Cally Roper of the London School of Hygiene & Tropical Medicine, used genetic methods to characterise how resistance to sulfadoxine has spread across Africa, with a view to determining its geographical origins in order to help improve measures aimed at controlling the spread of drug-resistant P. falciparum.

The team analysed blood samples collected from patients with malaria in various African countries, and searched the scientific literature for other similar studies. They discovered five major variant genetic sequences (three of which contain mutations that confer various degrees of resistance to sulfadoxine in laboratory tests) to be present in Africa, each with a unique geographical distribution. In particular, the data showed that malaria parasites in east and west Africa carry different resistance mutations.

The findings show that sulfadoxine-resistant parasites have emerged independently at multiple sites in Africa, and that the molecular basis for sulfadoxine resistance is different in east and west Africa. This latter result may have clinical implications because it suggests that the effectiveness of sulfadoxine as an antimalarial drug may vary across the continent. They also suggest that economic and transport infrastructures may have played a role in governing recent parasite dispersal across the continent through their influence on the volume of human migration.

Dr. Roper comments: 'Our findings suggest that the effectiveness of sulfadoxine as an antimalarial drug may vary across Africa. They also point to the need to co-ordinate malaria control campaigns across socioeconomically linked areas in Africa, rather than focusing solely on national territories, in order to more effectively reduce the malaria burden in the continent'


'/>"/>

Contact: Gemma Howe
gemma.howe@lshtm.ac.uk
44-782-861-7901
London School of Hygiene & Tropical Medicine
Source:Eurekalert

Related medicine news :

1. Discovery of sugar sensor in intestine could benefit diabetes
2. Discovery suggests location of genes for breast density, a strong risk factor for breast cancer
3. Stem cell research produces a key discovery for Fragile X Syndrome
4. Welch Foundation gives $1.6 million for drug discovery research
5. New discovery leaves blood-doping athletes scratching their heads
6. Chemical Diversity Initiates International Prostrate Cancer Discovery Partnership
7. New discovery leaves blood-doping athletes scratching their heads
8. Discovery of widespread tumor growth gene holds promise for effective anti-cancer treatment
9. Discovery supports theory of Alzheimers disease as form of diabetes
10. Discovery Health CME Explores the Benefits and Risks of Aspirin in Aspirin Therapy: Maximizing the Benefits
11. New discovery may improve treatment of one of the worlds leading causes of blindness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... ... The Radiology Business Management Association (RBMA) is pleased to announce ... process has been in place since the RBMA was founded in 1968 with all ... Jim Hamilton, MHA, CMM, FRBMA, as president. Dr. Dickerson the chief executive officer for ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... and College of Urgent Care Medicine will host industry leaders for the annual ... will help those in the industry adapt to the issues currently affecting urgent ...
(Date:4/28/2017)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, has ... which He does not. Yisrayl says with so many titles and names for the ... he says with a little Scripture, backed with a lot of research, the truth is ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... skincare and advanced nutraceutical supplements, through its Nova Skin Sciences division, recently ... hydrating benefits of a moisturizer with the power of an anti-aging concentrate. ...
(Date:4/28/2017)... ... 2017 , ... Christie Medical Holdings, Inc. , with its market-leading ... Medical Inc. , a leader in infusion therapy and pain management. , Intravenous ... percent of hospital patients receiving a peripheral IV catheter as part of their treatment ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , Tenn. and DALLAS , April 19, ... Inc., announced that the first patients in ... EndoStim device in the Lower Esophageal Sphincter Stimulation for ... minimally-invasive implantable device designed to provide long-term reflux control ... GERD affects nearly 65 million people in ...
(Date:4/19/2017)... , April 19, 2017  Novartis today announced ... National Heart, Lung, and Blood Institute (NHLBI) of ... 58% of patients with treatment-na├»ve severe aplastic anemia ... treated with eltrombopag at the initiation of and ... study evaluated three sequential treatment groups, or cohorts. ...
(Date:4/18/2017)... 18, 2017 Research and Markets has announced ... report to their offering. ... global arthroscopy devices market to grow at a CAGR of 6.35% ... Devices Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
Breaking Medicine Technology: